CareDx raises 2026 revenue outlook to $520M-$530M as it plans AlloHeme launch in Q1 2027 (NASDAQ:CDNA)

seekingalpha.com · 2026-10-30

CareDx Q3 2026 earnings: revenue jumps 39%, guidance rises, and AlloHeme launch stays on track.

TickrTrends take: CareDx's raised revenue guidance to a range of $520M to $530M for 2026 reflects management confidence in its commercial execution and the anticipated AlloHeme launch. Given TickrTrends' current overvalued assessment, investors should monitor whether the company can achieve these targets and sustain profitability growth sufficient to justify current valuation multiples in the Healthcare sector. The timing and commercial success of the AlloHeme launch in the first quarter of 2027 will be a critical variable for determining whether the stock's valuation gap narrows or widens.

Read the full story at seekingalpha.com →